

SEQUENCE LISTING

5 <110> Nycomed Imaging AS

 <120> Improvements in or relating to diagnostic/therapeutic
 agents

10 <130> REF/Klaveness/993

 <140> US 08/958,993

 <141> 1997-10-28

15 <160> 25

 <170> PatentIn Ver. 2.1

 <210> 1

20 <211> 4

 <212> PRT

 <213> Artificial Sequence

 <220>

25 <223> Description of Artificial
 Sequence:RGDC-Mal-PEG3400-DSPE

 <400> 1

 Arg Gly Asp Cys

30 1

 ~

 <210> 2

 <211> 25

35 <212> PRT

 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide
comprising phosphatidylserine-binding and
heparin-binding sections

5

<400> 2

Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Ala Ala
1 5 10 15

10 Ala Trp Glu Pro Pro Arg Ala Arg Ile
20 25

<210> 3

15 <211> 8

<212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Heparin-binding
peptide

<400> 3

25 Trp Glu Pro Pro Arg Ala Arg Ile
1 5

<210> 4

<211> 6

30 <212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence:Linker sequence

<220>

<221> MOD_RES

<222> (1)

<223> MTX-phenylalanine

<400> 4

5 Phe Lys Leu Arg Leu Cys
1 5

<210> 5

10 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:Heparin
sulphate binding peptide

<400> 5

Lys Arg Lys Arg
20 1

<210> 6

<211> 8

25 <212> PRT

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence:Fibronectin
peptide

<400> 6

Trp Gln Pro Pro Arg Ala Arg Ile
35 1 5

<210> 7

<211> 13

<212> PRT

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence:Lipopeptide
consisting of a heparin sulphate binding peptide
and a fibronectin peptide

10 <220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-lysine

15 <400> 7

Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile

1

5

10

20 <210> 8

<211> 24

<212> PRT

<213> Artificial Sequence

25 <220>

<223> Description of Artificial Sequence:Fibronectin
peptide sequence

<400> 8

30 Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly Gly

1

5

10

15

Gly Trp Gln Pro Pro Arg Ala Ile

20

35

<210> 9

<211> 6

<212> PRT

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence: Biotinylated
endothelin-1 peptide

<220>

10 <221> MOD_RES

<222> (1)

<223> Biotin-D-Trp

<400> 9

15 Trp Leu Asp Ile Ile Trp
1 5

<210> 10

20 <211> 10

<212> PRT

<213> Artificial Sequence

<220>

25 <223> Description of Artificial Sequence: Biotinylated
fibrin-anti-polymerant peptide

<220>

<221> MOD_RES

30 <222> (1)

<223> Biotinylated-Gly

<220>

<221> MOD_RES

35 <222> (10)

<223> AMIDATION

<400> 10

Gly Pro Arg Pro Pro Glu Arg His Gln Ser

1 5 10

5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Lipopeptide
containing RGD sequence and fluorescein reporter
group

15

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

20

<220>

<221> MOD_RES

<222> (4)

<223> Acetyl-RGD-K-fluorescein side chain

25

<400> 11

Lys Lys Lys Lys Gly

1 5

30

<210> 12

<211> 18

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Endothelial

cell binding lipopeptide

<220>

<221> MOD_RES

5 <222> (1)

<223> 2-n-hexadecylstearyl-Lys

<220>

<221> MOD_RES

10 <222> (18)

<223> AMIDATION

<400> 12

Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys

15 1 5 10 15

Leu Ala

20

<210> 13

<211> 4

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Lipopeptide
functionalised with captopril

30

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

35

<220>

<221> MOD_RES

<222> (4)

<223> Amide linked via side chain to captopril

<220>

<221> MOD_RES

5 <222> (4)

<223> AMIDATION

<400> 13

Lys Lys Lys Lys

10 1

<210> 14

<211> 13

15 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Lipopeptide

20 with an affinity for endothelial cells

<220>

<221> MOD_RES

<222> (1)

25 <223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

<222> (4)

30 <223> Acp

<220>

<221> MOD_RES

<222> (13)

35 <223> AMIDATION

<400> 14

Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu
1 5 10

5 <210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:Lipopeptide
comprising an interleukin-1 receptor binding
peptide

15 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

20 <400> 15
Lys Gly Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
1 5 10

25 <210> 16
<211> 12
<212> PRT
<213> Artificial Sequence

30 <220>
<221> MOD_RES
<222> (1)
<223> Dabsyl-Tyr

35 <220>
<221> MOD_RES
<222> (10)

<223> RGDS chain linked via NH2 group of lysine

<220>

5 <223> Description of Artificial Sequence: Branched core
peptide comprising a dabsylated atherosclerotic
plaque-binding sequence and RGDS

<400> 16

10 Tyr Arg Ala Leu Val Asp Thr Leu Lys Lys Gly Cys
1 5 10

<210> 17

<211> 25

15 <212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> misc_feature

<222> (1)

25 <223> Biotinylated

<400> 17

gaaaggtagt ggggtcgtgt gccgg

25

30

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Lipopeptide

with affinity for thrombi

<220>

<221> MOD_RES

5 <222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

10 <222> (15)

<223> AMIDATION

<400> 18

Lys Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln

15 1 5 10 15

<210> 19

<211> 6

20 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Lipopeptide

25

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

30

<220>

<221> MOD_RES

<222> (5)

<223> Biotinylated-Lys

35

<400> 19

Lys Trp Lys Lys Lys Gly

1 5

<210> 20

5 <211> 5

<212> PRT

<213> Artificial Sequence

<220>

10 <223> Description of Artificial
Sequence:Thiol-functionalised lipid molecule

<220>

<221> MOD_RES

15 <222> (1)

<223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

20 <222> (4)

<223> Acp

<400> 20

Lys Lys Lys Xaa Cys

25 1 5

<210> 21

30 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

35 <223> Description of Artificial Sequence:Lipopeptide
functionalised with atenolol

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

5

<220>

<221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
atenolol

10

<220>

<221> MOD_RES

<222> (4)

<223> AMIDATION

15

<400> 21

Lys Lys Lys Lys

1

20

<210> 22

<211> 4

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Lipopeptide
containing folic acid

30

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

35

<220>

<221> MOD_RES

<222> (4)

<223> AMIDATION

<220>

5 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
folic acid

10 <400> 22

Lys Lys Lys Lys

1

15 <210> 23

<211> 4

<212> PRT

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence:Lipopeptide
containing a derivative of bestatin

<220>

25 <221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

30 <221> MOD_RES

<222> (4)

<223> AMIDATION

<220>

35 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to

derivative of bestatin

<400> 23

Lys Lys Lys Lys

5 1

<210> 24

<211> 4

10 <212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:Lipopeptide
containing chlorambucil

<220>

<221> MOD_RES

<222> (1)

20 <223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

<222> (4)

25 <223> AMIDATION

<220>

<221> MOD_RES

<222> (4)

30 <223> Lysine with side chain linked via amide bond to
chlorambucil

<400> 24

Lys Lys Lys Lys

35 1

<210> 25

<211> 4

<212> PRT

<213> Artificial Sequence

5

<220>

<223> Description of Artificial Sequence:Lipopeptide
functionalised with sulphisoxazole

10

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

15

<220>

<221> MOD_RES

<222> (4)

<223> AMIDATION

20

<220>

<221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
sulphisoxazole

25

<400> 25

Lys Lys Lys Lys

1

30

<210> 26

<211> 9

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 26

Tyr Arg Ala Leu Val Asp Thr Leu Lys

1 5

5

<210> 27

<211> 16

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

15

<400> 27

Tyr Ala Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr

1 5 10 15

20

<210> 28

<211> 17

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 28

30

Arg Ala Leu Val Asp Thr Glu Phe Lys Val Lys Gln Glu Ala Gly Ala

1 5 10 15

Lys

35

<210> 29

<211> 14

<212> PRT

<213> Artificial Sequence

5 <220>

<223> Description of Artificial Sequence:Thrombus
binding peptide

<400> 29

10 Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10

<210> 30

15 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Thrombus
binding peptide

<400> 30

Gly Pro Arg Gly
25 1

<210> 31

<211> 13

30 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Platelet
35 binding peptide

<400> 31

Pro Leu Tyr Lys Lys Ile Ile Lys Lys Leu Leu Glu Ser

1

5

10

5

10

15

[illegible]